Filing Details
- Accession Number:
- 0001104659-19-065554
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-19 19:00:29
- Reporting Period:
- 2019-11-19
- Accepted Time:
- 2019-11-19 19:00:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc. | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578823 | T Ryan Sullivan | C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-11-19 | 8,325 | $53.41 | 34,043 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-11-19 | 8,325 | $85.00 | 25,718 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-11-19 | 3,829 | $85.00 | 21,889 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Disposition | 2019-11-19 | 8,325 | $0.00 | 8,325 | $53.41 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
26,475 | 2028-02-13 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 13, 2018.